Publication | Closed Access

Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers

Breast OncologyMedicineEstrogen ReceptorCancer GrowthGynecologyAsian Postmenopausal WomenBreast CancerCancer TreatmentOncologyRadiation OncologyTumor MicroenvironmentEndocrine-related CancerEr Expressional Change